1 terminated, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Elucida Oncology: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML ELU001 - Acute Myeloid Leukemia, AML, Childhood | Phase 1 | Withdrawn | Elucida Oncology | 2024-06-07 | 2024-08-07 | |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
Recurrence (2) · Carcinoma (1) · Carcinoma, Endometrioid (1) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Krukenberg Tumor (1) · Leukemia, Myeloid, Acute (1) · Ovarian Diseases (1) · Ovarian Neoplasms (1) · Uterine Diseases (1)
United States (1)